Monoclonal antibody

EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, CD3, Antigen, Northwest Biotherapeutics, Neurotoxicity, SITC, Immunotherapy, Neoplasm, Risk, Annual general meeting, Safety, Monoclonal antibody, Pharmaceutical industry, Vaccine

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, California, from November 3-5.

Key Points: 
  • EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, California, from November 3-5.
  • This poster presentation will feature initial safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data from the Phase I dose escalation study in relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).
  • The presentation details are as follows:
    “We are very pleased to share the EMB-06 data as a late-breaker at the SITC Annual Meeting.
  • “With multiple T cell engagers in our clinical and pre-clinical pipeline, EpimAb is looking forward to realizing the promising potential of this modality and to creating novel therapies for diseases with significant unmet need.”

United States Bispecific Antibodies Market & Clinical Pipeline Insight Report 2023-2028: Comprehensive Clinical Insight on 300 Bispecific Antibodies - Analysis by Company, Indication and Phase - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
General Health, Science, Health, Research, Neoplasm, FDA, Antibody, Alzheimer's disease, Antigen, Hope, Monoclonal antibody, Organization, Quality of life, Tissue, Traffic barrier, Immune system, Medicine, Cancer, DSM-IV codes, Infection, Investment, Drug resistance, Patient, Pharmaceutical industry, Vaccine

The "US Bispecific Antibodies Market & Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Bispecific Antibodies Market & Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Bispecific antibodies are being explored to target misfolded proteins implicated in neurodegenerative conditions like Alzheimer's and Parkinson's disease.
  • By specifically targeting these pathological proteins and facilitating their clearance, bispecific antibodies offer a potential disease-modifying approach.
  • US Bispecific Antibodies Market Opportunity: > USD 15 Billion By 2028
    Comprehensive Clinical Insight On Bispecific Antibodies In Pipeline: > 300 Antibodies
    US Bispecific Antibodies Clinical Pipeline Insight By Company, Indication and Phase

CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, October 17, 2023
University, Stanford Cancer Institute, Antibody, Monoclonal antibody, Division, Drug, Research, Trial of the century, Stanford University School of Medicine, MD, Mosunetuzumab, BLA, IND, Health, Biotechnology, Medicine, Disease, Cancer, Patient, BA, Therapy, B-cell lymphoma, CAR, NME, CD22, Publication, SAN, CD19, BMT, Acceleration, Baylor University, B Division (New York City Subway), NIH, Pharmaceutical industry, Nursing, Stanford University, Blood

SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
  • “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
  • With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
  • Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.

EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement

Retrieved on: 
Thursday, October 12, 2023
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Bispecific monoclonal antibody, Monoclonal antibody, ALM, Cancer, Patient, Dream, History, Protalix BioTherapeutics, Dermatology, Fine chemical, Vaccine, Almirall

EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, today announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.

Key Points: 
  • EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, today announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.
  • Under the terms of this agreement, Almirall will gain a license to utilize EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform technology to generate, develop and commercialize bispecific antibodies, for which Almirall will have exclusive global rights.
  • “We are pleased to partner with Almirall to expand the application of our FIT-Ig® technology beyond the oncology space,” said Dr. Chengbin Wu, CEO and founder of EpimAb.
  • EpimAb Biotherapeutics is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies.

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Congress, European Society for Medical Oncology, ESMO, Oncology, CET, Monoclonal antibody, Patient, Pharmaceutical industry, Vaccine

ROCKVILLE, Md.

Key Points: 
  • ROCKVILLE, Md.
  • and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, on Monday, October 23 at 12:00 p.m. CET.
  • First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors

Alopexx to Present Data on F598, a Novel, Broad-Spectrum Immunotherapeutic at IDWeek 2023

Retrieved on: 
Thursday, October 12, 2023
Diagnosis, Incidence, Disease, Immunoglobulin G, Fungal infection, Mortality, ESKAPE, Entrepreneurship, Infection, ICU, Pseudomonas aeruginosa, Tissue, Parasitism, Patient, Vaccine, MD, Monoclonal antibody

CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Alopexx, Inc., a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Daniel Vlock, MD, Co-Founder, Chief Executive Officer and Chairman of the Board of Alopexx, is scheduled to present at IDWeek's 2023's  New Antimicrobials in the Pipeline symposium being held October 11-15, 2023 in Boston, MA.

Key Points: 
  • Dr. Vlock will present pre-clinical and clinical data on Alopexx's monoclonal antibody (MAb) F598, a novel immunotherapeutic that targets PNAG.
  • MAbs as immunotherapies for infectious agents have a strong appeal but only a few are licensed for preventative use against limited diseases.
  • Extensively published pre-clinical results show MAb F598 can protect against a range of non-viral microbial infections and there is no detectable binding to human tissues.
  • "With the increasing incidence of antimicrobial resistant bacteria there is a pressing need for novel and alternative therapeutics.

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Monoclonal antibody, BGNE, Cancer, Quality of life, SSE, OX40, LAG3, Patient, Medicine, European, Entrepreneurship, PD-L1, Safety, Tislelizumab, Pharmaceutical industry, BeiGene, HPK1, Novartis

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).
  • “BeiGene will continue to work with Novartis on development, regulatory and manufacturing priorities.
  • BeiGene has agreed to provide Novartis with ongoing clinical supply of TEVIMBRA to support its clinical trials.
  • Under the agreement, Novartis was responsible for regulatory submissions and had the right to commercialize in these licensed countries following regulatory approval.

EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference

Retrieved on: 
Wednesday, September 20, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bispecific monoclonal antibody, Monoclonal antibody, Northwest Biotherapeutics, ESMO, Congress, Protein, European Society for Medical Oncology, PD-1, Tumor microenvironment, Safety, Pharmaceutical industry, Vaccine, Patient

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) Congress on October 23 (local time).

Key Points: 
  • EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) Congress on October 23 (local time).
  • This poster will feature initial safety, efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) data from the EMB-02 Phase I dose escalation study in advanced solid tumors (NCT04618393).
  • The EMB-02 bispecific antibody targets two checkpoint proteins, PD-1 and LAG-3, and restores effector T cell function through robust inhibition and degradation of the target proteins in the tumor microenvironment.
  • In addition, it has shown strong anti-tumor efficacy in in vivo tumor models resistant to standard anti-PD-1 monotherapies.

Biocytogen Officially Launches RenMice® Series

Retrieved on: 
Friday, September 15, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Monoclonal antibody, Antigen, Immunization, Human, Drug development, Therapy, Phla–Pherá languages, PMHC cellular microarray, TIL, HLA, G protein-coupled receptor, CMC, Immune tolerance, MHC, NK, Multimedia, Toxicity, Antibody, Medication, TCR, Knob, Service provider, TILS, HKEX, CTAS, Collection, KIH, Risk, Drug discovery, Epitope, Mouse, Mutagenesis, Spacecraft, Hook effect, Virus, CDR3, Safety, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
  • The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
  • View the full release here: https://www.businesswire.com/news/home/20230915794363/en/
    RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
    Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
  • As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Biocytogen Officially Launches RenMice® Series

Retrieved on: 
Friday, September 15, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Monoclonal antibody, Antigen, Immunization, Human, Drug development, Therapy, Phla–Pherá languages, PMHC cellular microarray, TIL, HLA, G protein-coupled receptor, CMC, Immune tolerance, MHC, NK, Multimedia, Toxicity, Antibody, Medication, TCR, Knob, Service provider, TILS, HKEX, CTAS, Collection, KIH, Risk, Drug discovery, Epitope, Mouse, Mutagenesis, Spacecraft, Hook effect, Virus, CDR3, Safety, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
  • The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
  • View the full release here: https://www.businesswire.com/news/home/20230914583107/en/
    RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
    Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
  • As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.